Blood Pressure Control According to the Prevalence of Diabetes in Renal Transplant Recipients

Size: px
Start display at page:

Download "Blood Pressure Control According to the Prevalence of Diabetes in Renal Transplant Recipients"

Transcription

1 Blood Pressure Control According to the Prevalence of Diabetes in Renal Transplant Recipients E. Zbroch, J. Malyszko, I. Glowinska, D. Maciorkowska, G. Kobus, and M. Mysliwiec ABSTRACT Hypertension is one of the most frequent complications of renal transplantation. About 70% to 90% of this population display either high blood pressure (BP) or require antihypertensive therapy. Diabetes mellitus is also a common finding among kidney transplant recipients. The aim of the study was to assess the BP control among kidney transplant recipients according to the prevalence of diabetes. This retrospective analysis included 172 renal transplant recipients of overall mean age 50 years and 51% males. Hypertension was present in 79% of patients. About one-third of the studied population showed abnormal blood pressures based on office measurements. The cohort was divided into two groups according to the presence of diabetes: group 1, diabetic patients (n 14) versus group 2, nondiabetics (n 158). Nondiabetic patients were significantly older than diabetic ones (61.5 versus 49 years; P.05) and their time after renal transplantation was longer (98.83 versus months, P.05). There was no difference in regard to hypertension prevalence, mean BP value, percentage of abnormal ( 140/90 mm Hg) BP values or glomerular filtration rate. Diabetic patients were prescribed less steroid. The main hypotensive drug used in whole cohort and in no-diabetic patients was a beta-blocker (n 64, 37%; n 4, 28%), patients with diabetes used beta-blockers and angiotensinconverting enzyme inhibitors at the same frequency (n 60, 37%). The main causative factor for hypertension appeared to be the calcineurin inhibitor. More aggressive antihypertensive treatment using combined drugs, including RAS blockers, might provide adequate BP control among renal transplant subjects with high cardiovascular risk. AS EARLY AS THE FRAMINGHAM STUDY, conducted in 1961, hypertension (HTN) and diabetes were identified as the main risk factors for cardiovascular diseases. 1 HTN is a common disorder among patients with both types of diabetes. 2,3 It about 33% of persons with 20 years and about 70% at 40 years of diabetes type 1. 2 Among newly diagnosed diabetes type 2 cases, about 40% are hypertensive. 4 HTN is also one of the most frequent complications of renal transplantation; about 70% to 90% of this population displays either high blood pressure (BP) or requires antihypertensive therapy. 5 An abnormal BP is a potent nonimmunologic risk factor that directly relates to patient and graft survivals. 6 Uncontrolled HTN not only leads to de novo congestive heart failure and coronary heart disease, but also may contribute to a reduced glomerular filtration rate (GFR). HTN after renal transplantation derives from the interactions of a variety of factors, some of which are related to the transplanted kidney, or the native kidneys or immunosuppressive medications. It increases over time after transplantation. 6 Diabetes mellitus is also a common finding in kidney transplant recipients. Type 2, new-onset diabetes mellitus after transplantation is a serious condition enhancing cardiovascular risk, affecting longterm allograft survival and increasing complication. It occurs among 2% to 53% of all solid organ transplantations with a component like HTN, attributable to the immunosuppressive medications. 7 Therefore, effective hypotensive and hypoglycemic treatment of renal transplant patients is a major mission of daily practice. 8 The aim of the present study was to assess BP control among kidney transplant recipients according to the prevalence of diabetes. From the Department of Nephrology and Transplantology with Dialysis Center, Medical University, Bialystok, Poland. Address reprint requests to Professor Jolanta Malyszko, Department of Nephrology and Transplantology, Medical University Bialystok, Zurawia14, Poland. jolmal@poczta.onet.pl /13/$ see front matter 2013 by Elsevier Inc. All rights reserved Park Avenue South, New York, NY Transplantation Proceedings, 45, (2013)

2 HYPERTENSION AND DIABETES 201 PATIENTS AND METHODS This retrospective analysis of medical documentation of 172 renal transplant recipients of mean age 50 years included 51% males and 49% females. We examined the medical history of hypertension and diabetes, the time of transplantation as well as the hypotensive and immunosuppressive treatments. Diabetes was diagnosed before transplantation in two type 1 diabics, both of whom were blind and, one also had toe amputations versus for type 2 cases wherein, it was the cause of end-stage kidney failure. In contrast as new-onset diabetes mellitus was observed in eight subjects after transplantation. Diabetic controls was judged by HbA1c target values below 7% as assessed by HPLC (high-pressure liquid chromatography). BP was measured twice (in the beginning and in the end; the mean value was the count), during each routine visit to the Outpatient Transplant Unit in the sitting position after 5- minute rest, using a manual sphygmomanometer with an arm cuff. We analyzed the arithmetic average of median values from three visits. Routine visits were scheduled every 2 to 3 months. The laboratory tests included red blood count, hemoglobin, creatinine, total cholesterol, triglycerides as well as cyclosporine or tacrolimus level. GFR was estimated using the simplified MDRD formula. The type and dose of hypotensive and immunosuppressive drugs the number and were analyzed in relation to BP control. According to the guidelines of Polish and European Society of Hypertension, 9 an abnormal BP was a value 140/90 mm Hg. HTN was defined as a hypotensive drug prescription or an abnormal BP. The hypotensive drugs included calcium channel blockers (CCB), angiotensinconverting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB), beta-blockers (BB), and diuretics. The immunosuppressive regimen of prevalent kidney transplant recipients consisted of calcineurin inhibitors (CNI), in combination with prednisone and azathioprine or mycophenolate mofetil. The study group was divided according to the presence of diabetes: group I diabetics versus group II nondiabetics. Statistical Analysis Data were expressed as mean values standard deviations (SD). The data were analyzed using Statistica 7.0 computer software. Examination of the distribution normality of variables employed the W Shapiro-Wilk test. The data were also transformed logarithmically to achieve a normal distribution, whenever possible. Normally distributed measurements are reported as mean values SD; nonnormally distributed data, as median and minimal maximal values. P.05 was considered statistically significant. RESULTS The mean age of the studied group was 50 years with 51% (n 88) men. HTN was present in 79% of patients. The overall mean BP was 130/80 mm Hg. The studied cohort was divided according to group I with diabetes (n 14, 8%) versus group II without diabetes (n 158). Group I patients were significantly older (P.05) and their time after renal transplantation longer (98.83 versus months, P.05). There was no difference between them in the presence of HTN, mean BP value, percentage of abnormal ( 140/90 mm Hg) BPs, GFR, or laboratory tests, including cyclosporine or tacrolimus level. The analysis of the kind of immunosuppressive therapy revealed lower doses of steroids in the diabetic group. The characteristics of the groups are demonstrated in Table 1. The following hypotensive drugs were used: BB (37%), CCB (27%), ACEI (23%), and diuretics (12%). The main hypotensive drug among patients without diabetes was a BB (28%), followed by CCB (21%), ACEI (21%), and diuretics (14%). For patients with diabetes, they were BB and ACEI in the same frequency (37%) followed by CCB (28%) and diuretics (12%). One was the mean number of hypotensive Table 1. Clinical and Biochemical Characteristics of the Studied Kidney Transplant Recipients According to the Presence of Diabetes Whole Study Group (n 172) Group I Patients With Diabetes (n 14; 8%) Group II Patients Without Diabetes (n 158) P Age (y) Male (%) 88 (51%) 8 (57%) 80 (57%) NS Time after kidney transplantation (mos) egfr (ml/min/1.73 m 2 ) NS Creatinine (mg/dl) NS Erythrocyte count (mln/ml) NS Hemoglobin (g/dl) NS Total cholesterol (mg/dl) NS Triglycerides (mg/dl) NS Serum cyclosporin level (ng/ml) NS Blood pressure (mm Hg) Systolic NS Diastolic NS Blood pressure 140/90 mm Hg 44 (25%) 3 (21%) 41 (25%) NS Presence of hypertension 153 (79%) 11 (78%) 123 (77%) NS Use of calcineurin inhibitors 167 (97%) 14 (100%) 153 (96%) NS Use of mycophenolate mofetil 124 (72%) 9 (64%) 115 (72%) NS Use of azathioprine 29 (16%) 2 (14%) 27 (17%) NS Use of steroids 111 (64%) 6 (40%) 105 (66%).023 egfr, estimated glomerular filtration rate; NS, not significant.

3 202 ZBROCH, MALYSZKO, GLOWINSKA ET AL drugs among all subjects regardless of diabetes diagnosis. The whole cohort of renal transplant recipients was analyzed according to the type of immunosuppressive therapy. CNI were prescribed for 97% (N 167) of patients. More of them were hypertensive compared with subjects free of CNI (98%; n 130 versus 92% n 36, P.04) and their mean BP value was higher (130/80 versus 120/70 mm Hg, P.05). They more frequently displayed diabetes (8%, n 14 versus 0%) or increased total cholesterol concentrations (Table 2). Steroids were used by 64% (n 111) of renal transplant recipients. Patients on steroid therapy showed a shorter time after transplantation than those withdrawn from this drug. Steroids users revealed a lower estimated GFR. The mean fasting glucose was lower and prevalence of diabetes less among the group not receiving steroids. DISCUSSION Hypertension and diabetes are main factors related to cardiovascular mortality and morbidity among the general population. 10 Kidney transplant patients are often affected by abnormal BP and impaired glucose tolerance, which directly relate to patient and graft survivals. 2,7 Hillebrand et al 11 suggested that BP control is a key target to achieve long-term graft survival, which was longer among subjects with well-controlled BP. HTN is one of the most frequent complications of renal transplantation; about 70% to 90% of this population either displayed a high BP or requires antihypertensive therapy. 1 Our cohort included 79% of kidney transplant recipients to be hypertensive. There are some discrepancies in the target BP for these patients. According to ESH/ESC and JNC 7 guidelines, the target BP should be less than 140/90 mm Hg in the general population. 12,13 However neither JNC 7 nor ESH/ESC guidelines, including the latest update from 2009, make recommendations for solid organ transplant recipients. The NICE guidelines (Guideline 1.9 C-CVD for hypertension in renal transplant patients) recommend a target BP lower than 130/80 mm Hg, similar to that in the 2009 KDIGO (Kidney Disease Improving Global Outcomes) guidelines. 14 However, NICE and KDIGO guidelines are based only on expert opinion of good practice. There have been no randomized prospective studies estimating the target BP in renal transplant recipients. The latest guidelines of the Polish Society of Hypertension, in 2011, have increased the target BP to 140/90 mm Hg, even among subjects with higher cardiovascular risk such as transplant patients. 9,15 For our cohort of kidney transplant recipients, we adopted that target value of BP observing abnormal BP ( 140/90 mm Hg) among 25% of patients, regardless of the presence of diabetes. Using the same criteria, Basiratnia et al 16 reported a higher BP in 25.7% of 66 kidney transplant recipients. Małyszko et al, 17 comparing BP control in two groups of high cardiovascular risk subjects coronary heart disease and kidney allograft recipients, demonstrated an abnormal value (above 130/80 mm Hg) in 60% of transplanted patients. Examining 1666 renal transplant recipients Kasikse et al 18 observed a BP below 140/90 mm Hg only in almost half of them (55%). However, the method of BP measurement may play a role, not only in the general population, but also among transplanted patients. Basiratnia et al 16 verified that the casual method of office BP measurement showed 8/17 subjects who were hypertensive to be normotensive by ambulatory BP monitoring (ABPM). Comparing office blood pressure and ABPM, Paripovic et al 19 observed ABPM to discuss 24% with masked hypertension and 21% with hidden uncontrolled HTN. Diabetes can lead to cardiovascular diseases and may affect blood pressure control. In a study of 369 treated subjects on chronic hemodialysis, Agarwal 20 observed the presence of diabetes to be associated with an higher rate of predialysis BP. We also observed a similar relation according to the presence of diabetes in our previous study of BP control among hemodialysis patients. 21 In the present study there were no difference in BP control and the prevalence of HTN between the groups with versus without diabetes. What is even more interesting, diabetic patients were Table 2. Clinical and Biochemical Characteristics of the Studied Kidney Transplant Recipients According to the Use of Calcineurin Inhibitors/Steroids Whole Group (n 172) Use of Calcineurin Inhibitors (n 167) Without Calcineurin Inhibitors (n 5) P Blood pressure (mm Hg) Systolic Diastolic Total cholesterol (mg/dl) Presence of hypertension 153 (79%) 130 (98%) 36 (92%).0443 Presence of diabetes 14 (8%) 14 (8%) 0 (0%) NS Use of Steroids (n 111) Without Steroids (n 61) Time after kidney transplantation (mons) Creatinine (mg/dl) egfr (ml/min/1.73 m 2 ) Fasting glucose (mg/dl) Presence of diabetes 14 (8%) 6 (5%) 8 (13%).023 egfr, estimated glomerular filtration rate; NS, not significant.

4 HYPERTENSION AND DIABETES 203 significantly older and their time after transplantation longer compared with those without diabetes. Only 40% of them compared to 66% of patients without diabetes were prescribed glucocorticosteroids, due to the tendency to complete withdrawal in long-term allografts. Our diabetic patients included those with diabetes type 1 and 2 as well as with new-onset diabetes after transplantation, which was more frequently diagnosed among patients prescribed tacrolimus, or were older, or were obese or overweight (data not shown). CNI, especially cyclosporine, play predominant roles in the pathophysiology of posttransplant HTN. The hypertensive effect of CNI depends on increased systemic vascular resistance due to arterial vasoconstriction. 5,6 CNI also reduce GFR and increase tubular reabsorption of sodium leading to salt and water retention and rise in BP. 6 CNI, especially tacrolimus, shows diabetogenic qualities. 22 The recent cross-sectional, multicenter study of Bohlke et al 23 confirmed that cyclosporine and glucocorticosteroids were independent predictors of high BP after kidney transplantation. We also reaffirmed this relationship: the CNI group was more often hypertensive or diabetic. Beside modifying their life style most kidney allograft recipients, require antihypertensive agents to treat HTN. 5 In a study of BP among 119 patients after renal transplantation, Wadei et al 24 described 71% to use two hypotensive drugs. In our cohort, the mean number of antihypertensive agents was one. Małyszko et al 17 reported that a study group of hypertensive patients after kidney transplantation required a mean of three hypotensive drugs. In turn, a Korean study of BP control in 3859 patients with type 2 diabetes, documented 65.4% to require monotherapy while 24.7% were prescribed two hypotensive agents. 25 No particular class of antihypertensive drugs is recommended for kidney transplant recipients. The choice of a drugs depends not only on their efficacy and tolerance but also their possible impact on the renal graft and their pharmacological interference with the immunosuppressive therapy. 6 CCB, particular dihydropyridine, are the most frequently prescribed hypotensive class of medications for patients after renal transplantation, namely 80% of subjects studied by Małyszko et al. 17 Another classes of hypotensive regimens useful in patients after transplantation are ACEI and ARB. Assessing BP control after heart compared with kidney transplantation Przybylowski et al 26 and ACEI were prescribed for 40%. Among our cohort the most used hypotensive drug was a BB. Among diabetic, the second was a CCB or ACEI. Patients without diabetes used BB and ACEI at the same frequency; in second position was CCA among that group. Type 2 diabetic Korean patients showed the main hypotensive drug to be an ARB (52.8%) and then a CCA (21.8%) with BB only used by 10.4%. 25 Due to prevalence of cardiac disease in this population BB are widely used for chronic kidney disease, particularly associated with hyperactivity of the sympathetic nervous system. 27 This phenomena may have influenced the wide use of BB among our cohort of kidney patients. In conclusion, HTN is a common finding in renal transplant recipients. About one-third of the studied population had an abnormal BP based on the office BP measurements. ABPM should be used to detect masked or hidden uncontrolled HTN in this population. There was no influence of diabetes on BP control. The main causative factor for HTN was CNI prescription. REFERENCES 1. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J 3rd. Factors of risk in the development of coronary heart disease six year follow-up experience. The Framingham Study. Ann Intern Med. 1961;55: Epstein M, Sowers JR: Diabetes mellitus and hypertension. Hypertension. 1992;19: Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001;37: Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens. 1993;11: Ponticelli C, Cucchiari D, Graziani G. Hypertension in kidney transplant recipients. Transpl Int. 2011;24: Wadei HM, Textor SC. Hypertension in the kidney transplant recipient. Transplant Rev (Orlando). 2010;24: Pham PT, Pham PM, Pham SV, Pham PA, Pham PC. New onset diabetes after transplantation (NODAT): an overview. Diabetes Metab Syndr. Obes. 2011;4: Dunn BL, Teusink AC, Taber DJ. Management of hypertension in renal transplant patients: a comprehensive review of nonpharmacologic and pharmacologic treatment strategies. Ann Pharmacother. 2010;44: Guidelines of Polish Society of Hypertension Arterial Hypertension. 2011;15: Paulis L, Unger T. Novel therapeutic targets for hypertension. Nat Rev Cardiol. 2010;7: Hillebrand U, Suwelack BM, Loley K, et al. Blood pressure, antihypertensive treatment, and graft survival in kidney transplant patients. Transpl Int. 2009;22: Mancia G, De Backer G, Dominiczak A, et al Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25: Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289: Available at: Guidelines.aspx. 15. Dunn BL, Teusink AC, Taber DJ, Hemstreet BA, Uber LA, Weimert NA. Management of hypertension in renal transplant patients: a comprehensive review of nonpharmacologic and pharmacologic treatment strategies. Ann Pharmacother. 2010;44: Basiratnia M, Esteghamati M, Ajami GH, et al. Blood pressure profile in renal transplant recipients and its relation to diastolic function: tissue Doppler echocardiographic study. Pediatr Nephrol. 2011;26: Małyszko J, Małyszko J, Bachórzewska-Gajewska H, Poniatowski B, Dobrzycki S, Mysliwiec M. Inadequate blood pressure control in most kidney transplant recipients and patients with coronary artery disease with and without complications. Transplant Proc. 2009;41: Kasiske BL, Anjum S, Shah R, et al. Hypertension after kidney transplantation. Am J Kidney Dis. 2004;43:

5 204 ZBROCH, MALYSZKO, GLOWINSKA ET AL 19. Paripovic D, Kostic M, Spasojevic B, Kruscic D, Peco-Antic A. Masked hypertension and hidden uncontrolled hypertension after renal transplantation. Pediatr Nephrol. 2010;25: Agarwal R. Epidemiology of interdialytic ambulatory hypertension and the role of volume excess. Am J Nephrol. 2011;34: Zbroch E, Maciorkowska E, Trusewicz W, Małyszko J, Myśliwiec M. Blood pressure control according to the presence of diabetes in haemodialysis patients. Nefrol Dial Pol. 2011;15: Weir MR, Fink JC. Risk for posttransplant diabetes mellitus with current immunosuppressive medication. Am J Kidney Dis. 1999;34: Bohlke M, Barcellos FC, Rocha M, Gomes RH, Terhorst L, Marini SS. Predictors of hypertension following successful renal transplantation: a population-based study. Transplant Proc. 2009;41: Wadei HM, Amer H, Taler SJ, et al. Diurnal blood pressure changes one year after kidney transplantation: relationship to allograft function, histology, and resistive index. J Am Soc Nephrol. 2007;18: Seo MH, Lee WJ, Park CY, et al. Management of blood pressure in patients with type 2 diabetes mellitus: a nationwide survey in Korean. Diabetes Metab J. 2011;35: Przybylowski P, Malyszko J, Malyszko JS, Kobus G, Sadowski J, Mysliwiec M. Blood pressure control in orthotopic heart transplant and kidney allograft recipients is far from satisfactory. Transplant Proc. 2010;42: Schlaich MP. Sympathetic activation in chronic kidney disease: out of the shadow. Hypertension. 2011;57:

Prevention of Heart Failure: What s New with Hypertension

Prevention of Heart Failure: What s New with Hypertension Prevention of Heart Failure: What s New with Hypertension Ali AlMasood Prince Sultan Cardiac Center Riyadh 3ed Saudi Heart Failure conference, Jeddah, 13 December 2014 Background 20-30% of Saudi adults

More information

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose. JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I

More information

Treating hypertension in kidney transplant recipients

Treating hypertension in kidney transplant recipients Treating hypertension in kidney transplant recipients Mark Mitsnefes, MD, MS Professor of Pediatrics Director, Clinical Translational Research Center Cincinnati Children s Hospital Medical Center University

More information

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation

More information

Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences

Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,

More information

Update on Current Trends in Hypertension Management

Update on Current Trends in Hypertension Management Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student

More information

Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM

Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Faculty Disclosure I have no financial interest to disclose No off-label use of medications will be discussed FIFTH ANNUAL SYMPOSIUM Recognize changes between

More information

Hypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)

Hypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B) Practice Guidelines and Principles: Guidelines and principles are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines and principles should be followed

More information

Diabetes and Hypertension

Diabetes and Hypertension Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for

More information

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University

More information

The CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES

The CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES ACE Inhibitor and Angiotensin II Antagonist Combination Treatment Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES No recommendations possible based on Level

More information

Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension)

Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension) Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension) Janice P. Lea, MD, MSc, FASN Professor of Medicine Chief Medical Director of Emory Dialysis ASH Clinical Specialist

More information

Egyptian Hypertension Guidelines

Egyptian Hypertension Guidelines Egyptian Hypertension Guidelines 2014 Egyptian Hypertension Guidelines Dalia R. ElRemissy, MD Lecturer of Cardiovascular Medicine Cairo University Why Egyptian Guidelines? Guidelines developed for rich

More information

Reframe the Paradigm of Hypertension treatment Focus on Diabetes

Reframe the Paradigm of Hypertension treatment Focus on Diabetes Reframe the Paradigm of Hypertension treatment Focus on Diabetes Paola Atallah, MD Lecturer of Clinical Medicine SGUMC EDL monthly meeting October 25,2016 Overview Physiopathology of hypertension Classification

More information

Hypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital

Hypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital Hypertension and obesity Dr Wilson Sugut Moi teaching and referral hospital No conflict of interests to declare Obesity Definition: excessive weight that may impair health BMI Categories Underweight BMI

More information

Dr Doris M. W Kinuthia

Dr Doris M. W Kinuthia Dr Doris M. W Kinuthia Objectives Normal blood pressures in children Measurement of blood pressure in children Aetiology of Hypertension in children Evaluation of children with hypertension Treatment of

More information

Evolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH)

Evolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH) Evolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH) Sidney C. Smith, Jr. MD, FACC, FAHA, FESC Professor of Medicine/Cardiology University of North Carolina

More information

DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE

DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal

More information

hypertension Head of prevention and control of CVD disease office Ministry of heath

hypertension Head of prevention and control of CVD disease office Ministry of heath hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension

More information

Reducing proteinuria

Reducing proteinuria Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors

More information

Combination Therapy for Hypertension

Combination Therapy for Hypertension Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP

More information

Hypertension and Cardiovascular Disease

Hypertension and Cardiovascular Disease Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,

More information

The Evolution To Treatment Of Hypertension With Advanced Formulation

The Evolution To Treatment Of Hypertension With Advanced Formulation The Evolution To Treatment Of Hypertension With Advanced Formulation Dr. Donald Ang MBChB (UK) FRCP (Edin) MD (UK) CCST Cardiology (UK) FESC (Europe) Consultant Cardiologist Island Hospital Penang High

More information

Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures

Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures Supplementary Data Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures Quintiles of Systolic Blood Pressure Quintiles of Diastolic Blood Pressure Q1 Q2

More information

Quality ID #122: Adult Kidney Disease: Blood Pressure Management National Quality Strategy Domain: Effective Clinical Care

Quality ID #122: Adult Kidney Disease: Blood Pressure Management National Quality Strategy Domain: Effective Clinical Care Quality ID #122: Adult Kidney Disease: Blood Pressure Management National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Intermediate

More information

CHAPTER 5 RENAL TRANSPLANTATION. Editor: Dr Goh Bak Leong

CHAPTER 5 RENAL TRANSPLANTATION. Editor: Dr Goh Bak Leong CHAPTER 5 RENAL TRANSPLANTATION Editor: Dr Goh Bak Leong Expert Panel: Dr Goh Bak Leong (Chair) Dato Dr (Mr) Rohan Malek Dr Wong Hin Seng Dr Fan Kin Sing Dr Rosnawati Yahya Dr S Prasad Menon Dr Tan Si

More information

ABSTRACT KEYWORDS: The prevalence of hypertension varies from percentages in all

ABSTRACT KEYWORDS: The prevalence of hypertension varies from percentages in all 85 P a g e International Standard Serial Number (ISSN): 2319-8141 International Journal of Universal Pharmacy and Bio Sciences 6(6): November-December 2017 INTERNATIONAL JOURNAL OF UNIVERSAL PHARMACY AND

More information

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS? HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL

More information

5.2 Key priorities for implementation

5.2 Key priorities for implementation 5.2 Key priorities for implementation From the full set of recommendations, the GDG selected ten key priorities for implementation. The criteria used for selecting these recommendations are listed in detail

More information

New Hypertension Guideline Recommendations for Adults July 7, :45-9:30am

New Hypertension Guideline Recommendations for Adults July 7, :45-9:30am Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July

More information

REACH Risk Evaluation to Achieve Cardiovascular Health

REACH Risk Evaluation to Achieve Cardiovascular Health Dyslipidemia and transplantation History: An 8-year-old boy presented with generalized edema and hypertension. A renal biopsy confirmed a diagnosis of focal segmental glomerulosclerosis (FSGS). After his

More information

Target Blood Pressure Attainment in Diabetic Hypertensive Patients: Need for more Diuretics? Waleed M. Sweileh, PhD

Target Blood Pressure Attainment in Diabetic Hypertensive Patients: Need for more Diuretics? Waleed M. Sweileh, PhD Target Blood Pressure Attainment in Diabetic Hypertensive Patients: Need for more Diuretics? Waleed M. Sweileh, PhD Associate Professor, Clinical Pharmacology Corresponding author Waleed M. Sweileh, PhD

More information

The Hypertension Clinic is a part of the Internal Medicine

The Hypertension Clinic is a part of the Internal Medicine Original Article Hypertension Registry at the Bangkok Hospital Medical Center: The First 7 Months Experience OBJECTIVE: The Hypertension Registry at the Bangkok Hospital Medical Center was established

More information

Hypertension Update Background

Hypertension Update Background Hypertension Update Background Overview Aaron J. Friedberg, MD Assistant Professor, Clinical Division of General Internal Medicine The Ohio State University Wexner Medical Center Management Guideline Comparison

More information

ALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)

ALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage

More information

Management of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine

Management of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Management of Hypertension M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Disturbing Trends in Hypertension HTN awareness, treatment and control rates are decreasing

More information

Hypertension Update. Aaron J. Friedberg, MD

Hypertension Update. Aaron J. Friedberg, MD Hypertension Update Aaron J. Friedberg, MD Assistant Professor, Clinical Division of General Internal Medicine The Ohio State University Wexner Medical Center Background Diagnosis Management Overview Guideline

More information

CHAPTER 14. Renal Transplantation

CHAPTER 14. Renal Transplantation 15th Report of the Malaysian RENAL TRANSPLANTATION CHAPTER 14 Renal Transplantation Editor: Dr. Goh Bak Leong Expert Panel: : Dato Dr. Dato Zaki Dr. Morad Zaik Morad Mohd (Chair) Zaher (Chair) Dr. Goh

More information

Maher Fouad Ramzy; MD, FACP Professor of Renal Medicine, Cairo University

Maher Fouad Ramzy; MD, FACP Professor of Renal Medicine, Cairo University Hypertension in Hemodialysis Patient Maher Fouad Ramzy; MD, FACP Professor of Renal Medicine, Cairo University Mechanism of HTN in HD patients Volume-dependent HTN ECV expansion. Volume-independent HTN

More information

Hypertension in Geriatrics. Dr. Allen Liu Consultant Nephrologist 10 September 2016

Hypertension in Geriatrics. Dr. Allen Liu Consultant Nephrologist 10 September 2016 Hypertension in Geriatrics Dr. Allen Liu Consultant Nephrologist 10 September 2016 Annual mortality (%) Cardiovascular Mortality Rates are Higher among Dialysis Patients 100 10 1 0.1 0.01 0.001 25-34

More information

In the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi

In the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi Is Choice of Antihypertensive Agent Important in Improving Cardiovascular Outcomes in High-Risk Hypertensive Patients? Commentary on Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators.

More information

Slide notes: References:

Slide notes: References: 1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory

More information

SELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%

SELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80% SELECTED ABSTRACTS The following are summaries of selected posters presented at the American Transplant Congress on May 5 9, 2007, in San Humar A, Gillingham KJ, Payne WD, et al. Review of >1000 kidney

More information

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977

More information

Guest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2

Guest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2 Public Health Live T 2 B 2 Chronic Kidney Disease in Diabetes: Early Identification and Intervention Guest Speaker Joseph Vassalotti, MD, FASN Chief Medical Officer National Kidney Foundation Thanks to

More information

What s In the New Hypertension Guidelines?

What s In the New Hypertension Guidelines? American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the

More information

New Clinical Trends in Geriatric Medicine. April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine

New Clinical Trends in Geriatric Medicine. April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine New Clinical Trends in Geriatric Medicine April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine Objectives Review current guidelines for blood pressure (BP) control in older adults

More information

RESISTENT HYPERTENSION. Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University

RESISTENT HYPERTENSION. Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University RESISTENT HYPERTENSION Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University Resistant Hypertension Blood pressure remaining above goal in spite of concurrent use of 3 antihypertensive

More information

How to Manage Resistant Hypertension Min Su Hyon, MD

How to Manage Resistant Hypertension Min Su Hyon, MD How to Manage Resistant Hypertension Min Su Hyon, MD Cardiovascular Medicine, Internal Medicine Soonchunhyang University College of Medicine Definition Resistant to conventional medical therapy Definition

More information

CHAPTER 5 RENAL TRANSPLANTATION. Editor: Dr Goh Bak Leong

CHAPTER 5 RENAL TRANSPLANTATION. Editor: Dr Goh Bak Leong CHAPTER 5 RENAL TRANSPLANTATION Editor: Dr Goh Bak Leong Expert Panel: Dr Goh Bak Leong (Chair) Dato Dr Zaki Morad Mohd Zaher Dato Dr (Mr) Rohan Malek Dr Fan Kin Sing Dr Lily Mushahar Dr Lim Soo Kun Dr

More information

Management of Hypertension in special groups. DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University

Management of Hypertension in special groups. DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University Management of Hypertension in special groups BY DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University AGENDA SPECIAL GROUPS SPECIFIC DRUDS FOR SPECIAL GROUPS TARGET BP FOR SPECIAL GROUPS:

More information

Hypertension Putting the Guidelines into Practice

Hypertension Putting the Guidelines into Practice Hypertension 2017 Putting the Guidelines into Practice Disclosures Relationships with commercial interests: Grants/Research Support: Speakers Bureau/Honoraria: Consulting Fees: Data Safety and Monitoring:

More information

CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES

CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES C. Liakos, 1 G. Vyssoulis, 1 E. Karpanou, 2 S-M. Kyvelou, 1 V. Tzamou, 1 A. Michaelides, 1 A. Triantafyllou, 1 P. Spanos, 1 C. Stefanadis

More information

Objectives. Describe results and implications of recent landmark hypertension trials

Objectives. Describe results and implications of recent landmark hypertension trials Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships

More information

The Seventh Report of the Joint National Commission

The Seventh Report of the Joint National Commission The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow-up of the Modification of Diet in Renal Disease Study Mark J. Sarnak, MD; Tom Greene, PhD; Xuelei Wang,

More information

Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease

Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Investigator Meeting 12 th September 2017 - Sheffield Prof Sunil Bhandari Consultant

More information

Hypertension in Systemic Diseases

Hypertension in Systemic Diseases Hypertension in Systemic Diseases Prof. Andrzej Więcek FRCP (Edin.), FERA Department of Nephrology, Transplantation and Internal Medicine Medical University of Silesia, Katowice, Poland Hypertension in

More information

Difficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair

Difficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair Difficult-to-Control & Resistant Hypertension Anthony Viera, MD, MPH, FAHA Professor and Chair Objectives Define resistant hypertension Discuss evaluation strategy for patient with HTN that appears difficult

More information

DEPARTMENT OF GENERAL MEDICINE WELCOMES

DEPARTMENT OF GENERAL MEDICINE WELCOMES DEPARTMENT OF GENERAL MEDICINE WELCOMES 1 Dr.Mohamed Omar Shariff, 2 nd Year Post Graduate, Department of General Medicine. DR.B.R.Ambedkar Medical College & Hospital. 2 INTRODUCTION Leading cause of global

More information

Intruduction PSI MODE OF ACTION AND PHARMACOKINETICS

Intruduction PSI MODE OF ACTION AND PHARMACOKINETICS Multidisciplinary Insights on Clinical Guidance for the Use of Proliferation Signal Inhibitors in Heart Transplantation Andreas Zuckermann, MD et al. Department of Cardio-Thoracic Surgery, Medical University

More information

Objectives. Kidney Complications With Diabetes. Case 10/21/2015

Objectives. Kidney Complications With Diabetes. Case 10/21/2015 Objectives Kidney Complications With Diabetes Brian Boerner, MD Diabetes, Endocrinology, and Metabolism University of Nebraska Medical Center Review screening for, and management of, albuminuria Review

More information

ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH

ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk

More information

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of

More information

Treating Hypertension in Individuals with Diabetes

Treating Hypertension in Individuals with Diabetes Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any

More information

Difficult to Treat Hypertension

Difficult to Treat Hypertension Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic

More information

Analytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health

Analytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health Analytical Methods: the Kidney Early Evaluation Program (KEEP) 2000 2006 Database Design and Study Participants The Kidney Early Evaluation program (KEEP) is a free, community based health screening program

More information

ADVANCES IN MANAGEMENT OF HYPERTENSION

ADVANCES IN MANAGEMENT OF HYPERTENSION Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%

More information

Hypertension Putting the Guidelines into Practice

Hypertension Putting the Guidelines into Practice Hypertension 2017 Putting the Guidelines into Practice Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or

More information

Effectiveness of Add-On Low-Dose Diuretics in Combination Therapy for Hypertension: Losartan/Hydrochlorothiazide vs. Candesartan/Amlodipine

Effectiveness of Add-On Low-Dose Diuretics in Combination Therapy for Hypertension: Losartan/Hydrochlorothiazide vs. Candesartan/Amlodipine 831 Original Article Hypertens Res Vol.3 (27) No.9 p.831-837 Effectiveness of Add-On Low-Dose Diuretics in Combination Therapy for Hypertension: Losartan/Hydrochlorothiazide vs. Candesartan/Amlodipine

More information

Hypertension frequently occurs early after liver

Hypertension frequently occurs early after liver Late Hypertension After Liver Transplantation: A Comparison of Cyclosporine and Tacrolimus (FK 506) Vincent J. Canzanello,* Stephen C. Textor,* Sandra J. Taler,* Lora L. Schwartz,* Michael K. Porayko,*

More information

Literature Review Transplantation

Literature Review Transplantation Literature Review 2010- Transplantation Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs University of

More information

Hypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town

Hypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the

More information

None. Disclosure: Relationships with Industry Conflicts of Interests. Learning Objectives: Participants will be able to:

None. Disclosure: Relationships with Industry Conflicts of Interests. Learning Objectives: Participants will be able to: 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) James W. Shaw, MD Memorial Lecture

More information

CHAPTER 5 RENAL TRANSPLANTATION

CHAPTER 5 RENAL TRANSPLANTATION CHAPTER 5 RENAL TRANSPLANTATION Editor: Dr. Goh Bak Leong Expert Panel: Dato Dr. Zaki Morad b Mohd Zaher (Chair) Dr. Goh Bak Leong (Co-Chair) Dr. Fan Kin Sing Dr. Lily Mushahar Mr. Rohan Malek Dr. S. Prasad

More information

Cedars Sinai Diabetes. Michael A. Weber

Cedars Sinai Diabetes. Michael A. Weber Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor

More information

Using the New Hypertension Guidelines

Using the New Hypertension Guidelines Using the New Hypertension Guidelines Kamal Henderson, MD Department of Cardiology, Preventive Medicine, University of North Carolina School of Medicine Kotchen TA. Historical trends and milestones in

More information

Long-Term Care Updates

Long-Term Care Updates Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart

More information

Hypertension Update Clinical Controversies Regarding Age and Race

Hypertension Update Clinical Controversies Regarding Age and Race Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT

More information

Objectives. JNC 7 Is Nice But What s Up With JNC 8? Why Do We Care? Hypertension Background: Prevalence

Objectives. JNC 7 Is Nice But What s Up With JNC 8? Why Do We Care? Hypertension Background: Prevalence JNC 7 Is Nice But What s Up With JNC 8? 37 th Annual CAPA Conference October 4 th 2013 Ignacio de Artola, Jr. M.D. Assistant Professor of Clinical Family Medicine Medical Director, Primary Care Physician

More information

Use of Antihypertensive Medications in Patients with type -2 Diabetes in Ajman, UAE

Use of Antihypertensive Medications in Patients with type -2 Diabetes in Ajman, UAE Use of Antihypertensive Medications in Patients with type -2 Diabetes in Ajman, UAE ORIGINAL ARTICLE Mohammed Arifulla 1, Lisha Jenny John 1, Jayadevan Sreedharan 2, Jayakumary Muttappallymyalil 3, Jenny

More information

신장환자의혈압조절 나기영. Factors involved in the regulation of blood pressure

신장환자의혈압조절 나기영. Factors involved in the regulation of blood pressure 신장환자의혈압조절 K/DOQI Clinical practice guidelines on Hypertension and Antihypertensive agents in CKD 나기영 Factors involved in the regulation of blood pressure Renal function curve MAP (mmhg) Central role of

More information

CURRICULUM VITAE July 5, Name Chang-Kwon Oh. Date of Birth August 15, 1961

CURRICULUM VITAE July 5, Name Chang-Kwon Oh. Date of Birth August 15, 1961 CURRICULUM VITAE July 5, 2014 Name Chang-Kwon Oh Date of Birth August 15, 1961 Present Academic & Hospital Appointment Professor, Department of Surgery Ajou University, School of Medicine Chief, Department

More information

CHAPTER 5 RENAL TRANSPLANTATION. Editor: Dr Rosnawati Yahya

CHAPTER 5 RENAL TRANSPLANTATION. Editor: Dr Rosnawati Yahya CHAPTER 5 Editor: Dr Rosnawati Yahya Expert Panels: Dr Rosnawati Yahya Dr Ng Kok Peng Dr Suryati Binti Yakaob Dr Mohd Zaimi Abd Wahab Dr Yee Seow Ying Dr Wong Hin Seng Contents 5. Stock and Flow of Renal

More information

Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use

Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use Baseline characteristics Users (n = 28) Non-users (n = 32) P value Age (years) 67.8 (9.4) 68.4 (8.5)

More information

ADVANCES IN MANAGEMENT OF HYPERTENSION

ADVANCES IN MANAGEMENT OF HYPERTENSION Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,

More information

HYPERTENSION IN CKD. LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL

HYPERTENSION IN CKD. LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL HYPERTENSION IN CKD LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL Stages in Progression of Chronic Kidney Disease and Therapeutic Strategies Complications Normal Increased risk Damage GFR

More information

Patterns of Anti-hypertensive Therapy in Diabetic Patients with and without Reduced Renal Function

Patterns of Anti-hypertensive Therapy in Diabetic Patients with and without Reduced Renal Function Saudi J Kidney Dis Transpl 2010;21(4):652-659 2010 Saudi Center for Organ Transplantation Saudi Journal of Kidney Diseases and Transplantation Original Article Patterns of Anti-hypertensive Therapy in

More information

OUT OF DATE. Choice of calcineurin inhibitors in adult renal transplantation: Effects on transplant outcomes

OUT OF DATE. Choice of calcineurin inhibitors in adult renal transplantation: Effects on transplant outcomes nep_734.fm Page 88 Friday, January 26, 2007 6:47 PM Blackwell Publishing AsiaMelbourne, AustraliaNEPNephrology1320-5358 2006 The Author; Journal compilation 2006 Asian Pacific Society of Nephrology? 200712S18897MiscellaneousCalcineurin

More information

Hypertension Management Controversies in the Elderly Patient

Hypertension Management Controversies in the Elderly Patient Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No

More information

Hiroyuki Daikuhara 1, Fumi Kikuchi 2 and Toshihiko Ishida 2. Introduction. Original Article

Hiroyuki Daikuhara 1, Fumi Kikuchi 2 and Toshihiko Ishida 2. Introduction. Original Article 447310DVR9410.1177/1479164112447310Daikuhara et al.diabetes and Vascular Disease Research 2012 Original Article The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan

More information

By Prof. Khaled El-Rabat

By Prof. Khaled El-Rabat What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating

More information

Resistant hypertension (HTN) is defined as a

Resistant hypertension (HTN) is defined as a Original Paper Evaluation and Treatment of Resistant or Difficult-to-Control Hypertension David Wojciechowski, DO; Vasilios Papademetriou, MD; Charles Faselis, MD; Ross Fletcher, MD An observational study

More information

Hypertension Management: A Moving Target

Hypertension Management: A Moving Target 9:45 :30am Hypertension Management: A Moving Target SPEAKER Karol Watson, MD, PhD, FACC Presenter Disclosure Information The following relationships exist related to this presentation: Karol E. Watson,

More information

Hypertension Management Focus on new RAAS blocker. Disclosure

Hypertension Management Focus on new RAAS blocker. Disclosure Hypertension Management Focus on new RAAS blocker Rameshkumar Raman M.D Endocrine Associates of The Quad Cities Disclosure Speaker bureau Abbott, Eli Lilly, Novo Nordisk, Novartis, Takeda, Merck, Solvay

More information

HTN talk_l Davis_ /28/2018

HTN talk_l Davis_ /28/2018 1 2 GUIDELINES PUBLISHED AHEAD OF PRINT NOV 13, 2017 = SAME DAY AS PUBLIC PRESENTATION LESLIE L DAVIS, PHD, RN, ANP-BC, FPCNA, FAANP, FAHA The New Guidelines Have Been Published! Whelton PK, Carey RM,

More information

Metabolic Syndrome and Chronic Kidney Disease

Metabolic Syndrome and Chronic Kidney Disease Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference

More information

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003 Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,

More information

Diabetes in Renal Patients. Contents. Understanding Diabetic Nephropathy

Diabetes in Renal Patients. Contents. Understanding Diabetic Nephropathy Diabetes in Renal Patients Contents Understanding Diabetic Nephropathy What effect does CKD have on a patient s diabetic control? Diabetic Drugs in CKD and Dialysis Patients Hyper and Hypoglycaemia in

More information

Blood Pressure Monitoring in Chronic Kidney Disease

Blood Pressure Monitoring in Chronic Kidney Disease Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT American

More information

Rationale: Objectives: Indication: Diabetes Mellitus, Type 2 Study Investigators/Centers: 300 physicians in 292 clinics Research Methods: Data Source:

Rationale: Objectives: Indication: Diabetes Mellitus, Type 2 Study Investigators/Centers: 300 physicians in 292 clinics Research Methods: Data Source: GSK Medicine: N/A Study No.: 112255 Title: A Korean, multi-center, nation-wide, cross-sectional, epidemiology study to identify prevalence of diabetic nephropathy in hypertensive patients with type 2 diabetes

More information